Breaking News

Horizon, Otsuka in Development and Commercialization Pact

July 25, 2014

To perform in-vitro cell line screening of OPDC candidates

Horizon Discovery Group’s newly aquired CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) to perform in vitro cell line screening of certain OPDC development candidates. Horizon will receive $835,000 for the work to be substantially completed this year.
 
Horizon CombinatoRx provides access to the cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations. 
 
Dr. Darrin M Disley, chief executive officer of Horizon Discovery Group, said, “The contract with OPDC represents the continued commercial traction of the CombinatoRx business following the acquisition which was in line with the strategy outlined at the time of Horizon’s IPO. We are delighted that OPDC has chosen to work with us on these screening projects.”
 
Edwin Rock, M.D., Ph.D., senior director, Global Clinical Development, OPDC, said, “As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms. Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent